valueequityanalysis.com

Independent, business-by-business valuations built from company filings — owner earnings, a ten-year outlook, and a bear / base / bull range. Search a ticker to see our estimate of what the business is worth.

Not investment advice. We are not registered investment advisers, and the people behind this site may hold or trade positions in companies analyzed here. Full disclosures.

Invesco Ltd. (IVZ) stock intrinsic value fair value estimate & owner earnings analysis

Margin of safety$23.00 ComplexityHigh Updated
$20.33 $45.43
bear $20.33 base $34.95 bull $45.43 margin of safety $23.00 market price* $28.20
Invesco is a global asset manager that ended 2025 with about $2.17 trillion of client assets across ETFs and index funds (including the Invesco QQQ Trust tracking the Nasdaq-100), active equity and fixed income funds, money-market funds, and institutional and private-markets mandates. It earns fees as a percentage of the assets it manages, so its revenue rises and falls with markets and with client flows. It also holds a minority stake in a Chinese joint venture, Invesco Great Wall; the company itself is Bermuda-incorporated, US-run and NYSE-listed. What the business earns. We measure the cash the business produces before paying its lenders and preferred shareholders: operating cash flow, with working-capital swings removed, less stock-based pay and the capital spending needed to keep the business running, less the cash that belongs to outside investors in funds Invesco consolidates onto its books. On that basis the business produced between $2.04 and $3.51 per share a year from 2020 through 2025 ($2.04 in 2020, $3.51 in 2021, $2.77 in 2022, $2.05 in 2023, $2.05 in 2024, $2.58 in 2025). That six-year stretch starts after the 2019 OppenheimerFunds acquisition and covers a full market cycle, from the 2021 peak through the 2022-2023 downturn, so we use its middle value, about $2.31 per share (roughly $1.05 billion a year), as the normal earning power of today's business. 2025's $2.58 was 26% above 2024, largely because rising markets lifted assets; we do not treat that as a new, higher normal. Two accounting corrections lowered some years compared with our previous estimate. Invesco wrote down the value of management contracts for its acquired US retail mutual funds by $1.25 billion in 2023 and $1.79 billion in 2025. Those write-downs cost no cash and we ignore them, but each came with a large tax accounting benefit ($309 million in 2023, $385 million in 2025) that also cost or saved no cash; our earlier figures had in effect counted those benefits as cash, which overstated 2023 and 2025. In the other direction, our earlier figures deducted gains that belonged to outside investors in consolidated funds twice, understating 2021. The corrected record is flatter and more believable: roughly $2 to $2.8 per share outside the 2021 peak. What changes from here. One real, completed change is not in that record: on December 20, 2025, the QQQ Trust converted from a unit investment trust, which paid Invesco no management fee on roughly $352 billion of average 2025 assets, into a regular ETF that pays Invesco a fee, at a lower expense ratio for investors. The filings do not state the net profit this adds. The first half of 2026 gives a guide: operating income rose from $492 million to $697 million, but rising markets explain part of that. We credit the conversion with $150 million a year of pre-tax profit in the base case (about $0.25 per share after tax), well below the first-half increase. Working against the business, the fee Invesco earns per dollar managed fell from 28.4 to 23.0 basis points between 2023 and 2025 as clients moved to cheaper index products, and the two write-downs show the legacy US active fund book shrinking. Net long-term inflows of $10 billion, $65 billion and $81 billion in 2023-2025 have so far only offset that: revenue was $6.15 billion in 2020 and $6.38 billion in 2025. We therefore credit no general growth in the base case. The prior estimate's mid-single-digit growth rate was not supported by that flat record. The most recent full year grew 26% in business cash flow; our first-year base figure ($2.56 per share) is slightly below 2025's actual $2.58, so it assumes no further gain from 2025's market-driven rise. What it owes. At June 30, 2026 Invesco owed $736 million on its $2.5 billion revolving credit line (expiring May 2030), a $500 million floating-rate term loan due May 2030 and $400 million of 5.375% notes due November 2043. It also has $2.51 billion of 5.9% perpetual preferred shares, held almost entirely by MassMutual, which are paid before common shareholders. Against that it held $915 million of cash, of which about $310 million must stay in regulated subsidiaries. Counting the 2043 notes at slightly less than face value (they cost below 6% for 17 more years), the claims ahead of common shareholders come to about $3.51 billion net, or $7.73 per share. The $500 million of notes that matured in January 2026 were repaid mostly by drawing on the credit line. Lender limits are loose: at end-2025 the leverage ratio was 0.73 against a 3.25 limit, and interest was covered 20 times. We left out Invesco's roughly $1.05 billion of joint-venture and similar stakes and about $400 million of seed and other investments, since their distributions already run through cash flow or they back employee deferred pay. This is the main change from our previous estimate. Before, we valued only the cash left after interest and preferred dividends, and assumed today's financing would stay in place forever at today's cost. Now we value the whole business first and subtract everything owed to lenders and preferred holders. Invesco also paid $1.74 billion in 2025 to retire $1.5 billion of the preferred (a $240 million premium), funded partly with $1 billion of new bank loans, so more of its financing is now bank debt that must be repaid or refinanced by 2030. Base case (about $34.95 per share): business cash flow of about $2.56 per share ($1.16 billion a year) with the QQQ fee included, held flat, with growth in index products offsetting shrinking active funds and falling fees, as it did from 2020 to 2025. We carry it on beyond ten years because the QQQ brand, the ETF lineup and the institutional and money-market franchises have sustained roughly this level of cash for a decade. The business is worth about $19.4 billion; after the $3.5 billion owed, the common equity is worth about $15.9 billion. Bear case (about $20.33 per share): a market decline like 2022, hitting the Nasdaq-100 technology stocks behind QQQ hardest (the filing names this AI-linked concentration as a risk). Business cash flow holds at the 2020/2023/2024 trough level of about $2.04 per share for three years with only half the QQQ fee benefit, then falls 2% a year indefinitely as outflows from active funds and fee cuts continue with nothing new offsetting them. The business is worth about $12.8 billion; after the $3.5 billion owed, equity is about $9.2 billion. Even in this case, cash flow of about $0.85 billion a year covers interest and preferred dividends (together about $0.23 billion) more than three times, so the 2030 bank maturities should be refinanceable. Bull case (about $45.43 per share): the QQQ conversion adds $250 million of pre-tax profit a year, still below the first-half 2026 increase, and the net inflows Invesco has shown for three straight years grow cash flow 2% a year for ten years, then level off. The business is worth about $24.2 billion; after the $3.5 billion owed, equity is about $20.6 billion. We did not include any continuation of the recent market rally, any profit gains from the Barings and LGT private-markets partnerships (not yet proven), or further preferred buybacks. What would make this wrong: a steeper fall in fees than 2023-2025, or losing QQQ's leading position among Nasdaq-100 funds, would push value toward the bear case. A QQQ profit contribution clearly above $150 million a year in audited results, without a decline in the rest of the business, would push it toward the bull case. We could not size the QQQ fee income directly from the filings; the next annual report should show it. Margin-of-safety price. Invesco's earnings move with markets, fees are under steady pressure, and more than $3.5 billion is owed ahead of the common shares. The estimate calls for a margin of about 34% below the base value, a margin-of-safety price of about $23, which is only modestly above the bear-case value.
Fiscal yearOwner's earningsMethodology
2025 $1.96 ▼
Recomputed 2026-09-28 (whole series) to correct two basis errors: (a) Invesco's cash-flow reconciliation has no separate deferred-tax line - deferred tax sits inside the receivables/payables changes, so the earlier series wrongly stripped it as working capital (overstated 2023 by $309M and 2025 by $385M, the tax benefits booked on the intangible impairments); (b) CFO already removes non-cash gains/losses of consolidated investment products (CIP), so deducting all NCI income double-counted them (e.g. 2021). OE = CFO - true working-capital change - SBC - maintenance capex - NCI cash share - preferred dividends. CFO=$1,525.3M; reported operating asset/liability changes=$-152.4M of which deferred tax=$-385.3M, so true WC change=$232.9M; SBC=$80.0M; capex=$84.3M, growth capex=$6.2M (capex ratio 1.996% x revenue increase; zero if revenue fell), maintenance capex=$78.1M; NCI income=$106.9M vs CIP non-cash (gains)/losses already removed in CFO=$67.9M, NCI cash share deducted=$39.0M (NCI income beyond CIP marks; rule: marks attributed to NCI up to its income when same sign); preferred dividends=$204.6M. OE=$890.7M; diluted shares=455.0M; OE/sh=$1.96. Cross-check: equals NI + D&A + impairments + deferred tax + other non-cash items - maintenance capex - NCI cash share - preferred dividends. Source: accession 0000914208-26-000079.
2024 $1.41 ▼
Recomputed 2026-09-28 (whole series) to correct two basis errors: (a) Invesco's cash-flow reconciliation has no separate deferred-tax line - deferred tax sits inside the receivables/payables changes, so the earlier series wrongly stripped it as working capital; (b) CFO already removes non-cash gains/losses of consolidated investment products (CIP), so deducting all NCI income double-counted them. OE = CFO - true working-capital change - SBC - maintenance capex - NCI cash share - preferred dividends. CFO=$1,190.0M; reported operating asset/liability changes=$101.5M of which deferred tax=$-38.1M, so true WC change=$139.6M; SBC=$104.6M; capex=$69.1M, growth capex=$7.0M (capex ratio 1.996% x revenue increase; zero if revenue fell), maintenance capex=$62.1M; NCI income=$-22.4M vs CIP non-cash (gains)/losses already removed in CFO=$-57.9M, NCI cash share deducted=$0.0M (NCI income beyond CIP marks; rule: marks attributed to NCI up to its income when same sign); preferred dividends=$236.8M. OE=$646.9M; diluted shares=457.7M; OE/sh=$1.41. Cross-check: equals NI + D&A + impairments + deferred tax + other non-cash items - maintenance capex - NCI cash share - preferred dividends. Source: accession 0000914208-25-000114.
2023 $1.38 ▼
Recomputed 2026-09-28 (whole series) to correct two basis errors: (a) Invesco's cash-flow reconciliation has no separate deferred-tax line - deferred tax sits inside the receivables/payables changes, so the earlier series wrongly stripped it as working capital (overstated this year by $309M, the tax benefit on the $1,248.9M intangible impairment); (b) CFO already removes non-cash gains/losses of consolidated investment products (CIP), so deducting all NCI income double-counted them. OE = CFO - true working-capital change - SBC - maintenance capex - NCI cash share - preferred dividends. CFO=$1,300.8M; reported operating asset/liability changes=$-154.4M of which deferred tax=$-309.2M, so true WC change=$154.8M; SBC=$114.6M; capex=$164.3M, growth capex=$0.0M (revenue fell), maintenance capex=$164.3M; NCI income=$-71.3M vs CIP non-cash (gains)/losses already removed in CFO=$-176.3M, NCI cash share deducted=$0.0M (NCI income beyond CIP marks; rule: marks attributed to NCI up to its income when same sign); preferred dividends=$236.8M. OE=$630.3M; diluted shares=456.2M; OE/sh=$1.38. Cross-check: equals NI + D&A + impairments + deferred tax + other non-cash items - maintenance capex - NCI cash share - preferred dividends. Source: accession 0000914208-24-000219.
2022 $2.11 ▼
Recomputed 2026-09-28 (whole series) to correct two basis errors: (a) Invesco's cash-flow reconciliation has no separate deferred-tax line - deferred tax sits inside the receivables/payables changes, so the earlier series wrongly stripped it as working capital; (b) CFO already removes non-cash gains/losses of consolidated investment products (CIP), so deducting all NCI income double-counted them. OE = CFO - true working-capital change - SBC - maintenance capex - NCI cash share - preferred dividends. CFO=$703.2M; reported operating asset/liability changes=$-758.3M of which deferred tax=$48.3M, so true WC change=$-806.6M; SBC=$106.2M; capex=$192.9M, growth capex=$0.0M (revenue fell), maintenance capex=$192.9M; NCI income=$4.8M vs CIP non-cash (gains)/losses already removed in CFO=$-126.9M (opposite sign, so none attributed to NCI), NCI cash share deducted=$4.8M; preferred dividends=$236.8M. OE=$969.1M; diluted shares=459.5M; OE/sh=$2.11. Cross-check: equals NI + D&A + impairments + deferred tax + other non-cash items - maintenance capex - NCI cash share - preferred dividends. Source: accession 0000914208-23-000297 (CIP marks per FY2024 10-K 0000914208-25-000114).
2021 $2.81 ▼
Recomputed 2026-09-28 (whole series) to correct two basis errors: (a) Invesco's cash-flow reconciliation has no separate deferred-tax line - deferred tax sits inside the receivables/payables changes, so the earlier series wrongly stripped it as working capital; (b) CFO already removes non-cash gains/losses of consolidated investment products (CIP), so deducting all NCI income double-counted them (this year the earlier series deducted $339.6M of NCI income that was almost entirely non-cash CIP gains already excluded from CFO). OE = CFO - true working-capital change - SBC - maintenance capex - NCI cash share - preferred dividends. CFO=$1,078.1M; reported operating asset/liability changes=$-622.1M of which deferred tax=$79.7M, so true WC change=$-701.8M; SBC=$140.1M; capex=$108.8M, growth capex=$15.0M (capex ratio 1.996% x revenue increase), maintenance capex=$93.8M; NCI income=$339.6M vs CIP non-cash gains already removed in CFO=$390.0M, NCI cash share deducted=$0.0M (NCI income beyond CIP marks; rule: marks attributed to NCI up to its income when same sign); preferred dividends=$236.8M. OE=$1,309.2M; diluted shares=465.4M; OE/sh=$2.81. Cross-check: equals NI + D&A + impairments + deferred tax + other non-cash items - maintenance capex - NCI cash share - preferred dividends. Source: accession 0000914208-22-000319.
2020 $1.32 ▼
Recomputed 2026-09-28 (whole series) to correct two basis errors: (a) Invesco's cash-flow reconciliation has no separate deferred-tax line - deferred tax sits inside the receivables/payables changes, so the earlier series wrongly stripped it as working capital; (b) CFO already removes non-cash gains/losses of consolidated investment products (CIP), so deducting all NCI income double-counted them. OE = CFO - true working-capital change - SBC - maintenance capex - NCI cash share - preferred dividends. CFO=$1,230.3M; reported operating asset/liability changes=$146.6M of which deferred tax=$81.3M, so true WC change=$65.3M; SBC=$188.5M; capex=$115.0M, growth capex=$0.6M (capex ratio 1.996% x revenue increase), maintenance capex=$114.4M; NCI income=$45.9M vs CIP non-cash gains already removed in CFO=$32.1M, NCI cash share deducted=$13.8M (NCI income beyond CIP marks; rule: marks attributed to NCI up to its income when same sign); preferred dividends=$236.8M. OE=$611.5M; diluted shares=462.5M; OE/sh=$1.32. Cross-check: equals NI + D&A + impairments + deferred tax + other non-cash items - maintenance capex - NCI cash share - preferred dividends. Source: accession 0000914208-21-000331.
2019 $1.23 ▼
Recomputed 2026-09-28 (whole series) to correct two basis errors: (a) Invesco's cash-flow reconciliation has no separate deferred-tax line - deferred tax sits inside the receivables/payables changes, so the earlier series wrongly stripped it as working capital; (b) CFO already removes non-cash gains/losses of consolidated investment products (CIP), so deducting all NCI income double-counted them. OE = CFO - true working-capital change - SBC - maintenance capex - NCI cash share - preferred dividends. CFO=$1,116.6M; reported operating asset/liability changes=$139.0M of which deferred tax=$22.1M, so true WC change=$116.9M; SBC=$207.5M; capex=$124.3M, growth capex=$16.0M (capex ratio 1.996% x revenue increase), maintenance capex=$108.3M; NCI income=$49.5M vs CIP non-cash gains already removed in CFO=$32.9M, NCI cash share deducted=$16.6M; preferred dividends=$123.6M (partial year; preferred issued May 2019 with the OppenheimerFunds acquisition). OE=$543.7M; diluted shares=440.5M; OE/sh=$1.23. Transition year (partial-year acquisition), excluded from anchor window. Cross-check: equals NI + D&A + impairments + deferred tax + other non-cash items - maintenance capex - NCI cash share - preferred dividends. Source: accession 0000914208-20-000245 (figures confirmed in FY2021 10-K comparatives 0000914208-22-000319).
2018 $2.51 ▼
Recomputed 2026-09-28 (whole series) to correct two basis errors: (a) Invesco's cash-flow reconciliation has no separate deferred-tax line - deferred tax sits inside the receivables/payables changes, so the earlier series wrongly stripped it as working capital; (b) CFO already removes non-cash gains/losses of consolidated investment products (CIP), so deducting all NCI income double-counted them. OE = CFO - true working-capital change - SBC - maintenance capex - NCI cash share - preferred dividends. CFO=$828.8M; reported operating asset/liability changes=$-439.3M of which deferred tax=$37.5M, so true WC change=$-476.8M; SBC=$172.4M; capex=$102.5M, growth capex=$3.1M (capex ratio 1.996% x revenue increase), maintenance capex=$99.4M; NCI income=$0.3M vs CIP non-cash losses already removed in CFO=$-55.1M (opposite sign, none attributed to NCI), NCI cash share deducted=$0.3M; no preferred outstanding. OE=$1,033.5M; diluted shares=412.5M; OE/sh=$2.51. Cross-check: equals NI + D&A + deferred tax + other non-cash items - maintenance capex - NCI cash share. Source: accession 0000914208-19-000195.
2017 $2.38 ▼
Recomputed 2026-09-28 (whole series) to correct two basis errors: (a) Invesco's cash-flow reconciliation has no separate deferred-tax line - deferred tax sits inside the receivables/payables changes, so the earlier series wrongly stripped it as working capital (here the $51.7M deferred tax benefit, largely the 2017 US tax-reform remeasurement, is non-cash and now excluded); (b) CFO already removes non-cash gains/losses of consolidated investment products (CIP), so deducting all NCI income double-counted them. OE = CFO - true working-capital change - SBC - maintenance capex - NCI cash share - preferred dividends. CFO=$1,157.8M (restated, per FY2018 10-K comparative; originally $1,370.7M); reported operating asset/liability changes=$-146.3M of which deferred tax=$-51.7M, so true WC change=$-94.6M; SBC=$175.3M; capex=$111.7M, growth capex=$8.5M (capex ratio 1.996% x revenue increase), maintenance capex=$103.2M; NCI income=$33.7M vs CIP non-cash gains already removed in CFO=$81.0M, NCI cash share deducted=$0.0M; no preferred outstanding. OE=$973.9M; diluted shares=409.9M; OE/sh=$2.38. Cross-check: equals NI + D&A + deferred tax + other non-cash items - maintenance capex - NCI cash share. Source: accession 0000914208-19-000195 (FY2018 10-K comparative; originally 0000914208-18-000255).
2016 $1.99 ▼
Recomputed 2026-09-28 (whole series) to correct two basis errors and use the latest restated figures: (a) Invesco's cash-flow reconciliation has no separate deferred-tax line - deferred tax sits inside the receivables/payables changes, so the earlier series wrongly stripped it as working capital; (b) CFO already removes non-cash gains/losses of consolidated investment products (CIP), so deducting all NCI income double-counted them; (c) CFO and working capital now taken from the restated FY2018 10-K comparatives. OE = CFO - true working-capital change - SBC - maintenance capex - NCI cash share - preferred dividends. CFO=$654.0M (restated; originally $129.3M, the difference being CIP classification); reported operating asset/liability changes=$-468.5M of which deferred tax=$15.4M, so true WC change=$-483.9M; SBC=$159.7M; capex=$147.7M, growth capex=$0.0M (revenue fell), maintenance capex=$147.7M; NCI income=$14.1M vs CIP non-cash gains already removed in CFO=$7.4M, NCI cash share deducted=$6.7M; no preferred outstanding. OE=$823.8M; diluted shares=415.0M; OE/sh=$1.99. Cross-check: equals NI + D&A + deferred tax + other non-cash items - maintenance capex - NCI cash share. Source: accession 0000914208-19-000195 (FY2018 10-K restated comparatives; originally FY2016 10-K 0000914208-17-000328).

Owner's earnings per share by fiscal year, most recent first. Tap a row to see how that figure was calculated, including the source filing.

Sales geography
Predominantly the United States (about three-quarters of 2025 operating revenue, nationwide across the Northeast, Midwest, South and West), with about one-fifth from Europe (mainly the United Kingdom and continental Europe) and about 5% from Asia-Pacific (including Japan and Hong Kong).
Historical growth strategy

We don't have historical growth strategy information for this company yet.

Chart analysis
A chartist would see IVZ in a strong recovery uptrend. After years in a broad range, roughly the mid-teens to about $20 from 2022 to mid-2025 (with a sharp spring-2025 washout toward the low teens), the shares rallied steadily through late 2025 into 2026, from the low-to-mid $20s to a peak near $33 in August 2026, pushing through the 2021 highs in the high $20s. The stock has since eased to about $30, which a chartist would read as a pullback that keeps the pattern of higher highs and higher lows intact. The former high-$20s resistance is now the first support. Over the long run the stock is still well below its 2017-2018 highs in the high $30s, which remain overhead resistance, so a chartist would call it a breakout from a multi-year base within a longer-term range rather than a new secular uptrend.
Competitors

We don't have competitor information for this company yet.

Circle of competence

We don't have circle of competence information for this company yet.